THE MASTHEAD ~ ABOUT
About PT-141 Prescribed.
Who publishes this, what "Prescribed" means here, and the line we hold between summarizing the record and dispensing advice.
What this publication is
PT-141 Prescribed reads the bremelanotide record the way a broadsheet reads a public file — the approved indication in banner type, the contested effect beside the re-analysis, the tolerability cost run in full. No clinic sits behind the masthead and no clinicians are on staff; the desk diagnoses no one, writes no scripts, and gives no medical advice. It sells, sources, and brokers nothing. What it prints is the record, attributed and checked.
We read PT-141 the way a broadsheet reads a public record: lead with what was measured, attribute it to the source, mark plainly where the evidence is established, where it is disputed, and where it runs out. The drug's story is unusually well-suited to that treatment — a real FDA approval, a genuinely contested effect size, and a tolerability profile worth stating in full rather than soft-pedaling.
What "Prescribed" means here
The word "Prescribed" in this site's name is editorial framing, not a service. It signals the register we work in — the on-the-record, approved-label voice, reading bremelanotide as a real medicine with a real label, rather than as an internet curiosity. It does not mean this site prescribes anything, offers consultations, fills scripts, or connects readers to anyone who does. There is no clinic behind the masthead.
That distinction matters because bremelanotide genuinely is a prescription drug for one indication — and precisely because it is real and approved, the temptation to blur "approved" into "approved for you" is strong. We hold the line: we describe the approved indication, the labeled dose figures, and the trial findings as facts of record, and we recommend nothing to any individual.
How we handle evidence
Every quantitative clinical claim on this site is tied to a numbered citation in the references list — a trial, the FDA prescribing information, or a safety monograph. We keep two layers strictly apart: the cited clinical evidence, and a clearly-labelled, unverified layer of community field reports that we never attribute to a journal and never present as data. When the record is contested — as it is over the size of the desire effect — we say so and cite the dissent, rather than choosing a side for the reader. The aim is a lasting, honest reference: what bremelanotide has been shown to do, what it costs in tolerability, and where the open questions remain.